Key result
Atorvastatin improves RV basal strain ~10% over placebo in stable COPD, with reduced hsCRP.
Why the study?
Inflammation plays an important role in COPD and statins are believed to have anti-inflammatory effects beyond cholesterol reduction, but their effect on right ventricular function in COPD patients is unclear.
Does atorvastatin improve right ventricular function and inflammatory markers in patients with COPD?
RCT (n=76)
Double-blind
Random block permutation method
No
Does atorvastatin improve right ventricular function and inflammatory markers in patients with COPD?
Absolute Event Rate: -26.71% vs -24.31%
p-value: p=0.03
Improves right ventricular strain in stable COPD; extends statin pleiotropy evidence to respiratory disease.
Inflammation has an important role in chronic obstructive pulmonary diseases (COPD) and statins are believed to have anti-inflammatory effects beyond low-density lipoprotein cholesterol reduction. This study aimed to assess the effect of statin on the function of the right ventricle and inflammatory markers in COPD patients.
No takes yet. Share an insight, caveat, or question.
Hoorak et al. (2018) conducted an RCT in Chronic Obstructive Pulmonary Disease (COPD) (n=76). Atorvastatin vs. Placebo was evaluated on Right ventricular longitudinal strain in the basal segment (RV SRB) (p=0.03). Atorvastatin 40 mg/day significantly improved right ventricular basal longitudinal strain (p=0.03) and decreased hsCRP (p=0.03) compared to placebo over 3 months in patients with stable COPD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: